Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE New Chugai Inaugurated
October 7, 2002
-
ARCHIVE Relief of Lower Back Pain Increases Patients' Satisfaction with Osteoporosis Drugs
October 7, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
October 7, 2002
-
ARCHIVE Pharma Delegates Provides Opportunity to Open Communication: Chairman Brrunger
September 30, 2002
-
ARCHIVE eCTD Reaches Final ICH Step 4 at Washington Meeting
September 30, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
September 30, 2002
-
ARCHIVE Scientific Partner System Motivates MRs: Banyu
September 30, 2002
-
ARCHIVE BULLETIN
September 30, 2002
-
ARCHIVE Universal Health Insurance System Must Be Maintained at the Peak of Aging
September 30, 2002
-
ARCHIVE Eiken, Teramecs: Loopamp Real-time Turbidimeter LA-200
September 30, 2002
-
ARCHIVE Fujisawa Licenses Tacrolimus-coated Stents to Italy
September 30, 2002
-
ARCHIVE Sysmex: BACTANA to Detect Bacteria in Food
September 30, 2002
-
ARCHIVE Korosho to Develop Drug Safety Prediction System
September 30, 2002
-
ARCHIVE BD Japan: BD BBL CultureSwab EZII
September 30, 2002
-
ARCHIVE Drafting of GL for Physician-led Clinical Trials Progresses
September 30, 2002
-
ARCHIVE RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 30, 2002
-
ARCHIVE Ivermectin, Micafungin Recommended for Approval
September 30, 2002
-
ARCHIVE FDA's Registration Criteria for Drugs to Treat Obesity Outlined: JHSF Seminar
September 30, 2002
-
ARCHIVE Korosho to Shortly Propose Policy for Health Insurance Reform: Senior Official
September 30, 2002
-
ARCHIVE b-blockers Not Always More Effective than Ca Antagonists
September 30, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…